- Home
- HUBC vs APRE Comparison
HUBC vs APRE Comparison
Compare HUBC & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUBC
- APRE
- Stock Information
- Founded
- HUBC 2017
- APRE 2006
- Country
- HUBC Israel
- APRE United States
- Employees
- HUBC N/A
- APRE N/A
- Industry
- HUBC
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HUBC
- APRE Health Care
- Exchange
- HUBC Nasdaq
- APRE Nasdaq
- Market Cap
- HUBC N/A
- APRE 13.5M
- IPO Year
- HUBC N/A
- APRE 2019
- Fundamental
- Price
- HUBC $3.14
- APRE $1.80
- Analyst Decision
- HUBC
- APRE Strong Buy
- Analyst Count
- HUBC 0
- APRE 2
- Target Price
- HUBC N/A
- APRE $15.50
- AVG Volume (30 Days)
- HUBC 155.1K
- APRE 21.0K
- Earning Date
- HUBC 12-13-2024
- APRE 05-13-2025
- Dividend Yield
- HUBC N/A
- APRE N/A
- EPS Growth
- HUBC N/A
- APRE N/A
- EPS
- HUBC N/A
- APRE N/A
- Revenue
- HUBC $33,357,000.00
- APRE $1,502,581.00
- Revenue This Year
- HUBC N/A
- APRE N/A
- Revenue Next Year
- HUBC N/A
- APRE N/A
- P/E Ratio
- HUBC N/A
- APRE N/A
- Revenue Growth
- HUBC N/A
- APRE 157.63
- 52 Week Low
- HUBC $2.65
- APRE $1.85
- 52 Week High
- HUBC $21.70
- APRE $6.70
- Technical
- Relative Strength Index (RSI)
- HUBC 35.15
- APRE 26.70
- Support Level
- HUBC $2.65
- APRE $1.85
- Resistance Level
- HUBC $3.72
- APRE $2.30
- Average True Range (ATR)
- HUBC 0.74
- APRE 0.16
- MACD
- HUBC -0.11
- APRE -0.01
- Stochastic Oscillator
- HUBC 12.97
- APRE 2.50
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.